Market Summary | Major Indices | Market Movers | Market Sectors | Mutual Funds | A-Z Stock Listings
ETF Screener | World Markets | Currencies | CEO Wealthmeter | Oil / Energy | Metals
Treasury Rates | Calculators | My Watchlist | My Portfolio
         Symbol Lookup
ABRAXIS BIO Add to My Watchlist (NSDQ: ABII) 
Detailed Quote
News
Chart
SEC Filings
Profile
Historical
Options
     Abraxis 35.11 -0.11 (-0.31%) 41,733
11755 Wilshire Blvd.
Suite 2000
Los Angeles, CA 90025 US
(310) 883-1300
(310) 998-8553 fax
www.abraxisbio.com
CEO Bruce J. Wendel
Auditor Ernst & Young LLP
Exchange Traded NQ
ISIN Number US00383Y1029
CIK Number 1409012
NAICS Code 325412
Business Summary
An integrated biotechnology Company, which is engaged in the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses.
Number of Employees 734
Share Fundamentals
Market Cap 1.41B
Shares Outstanding 40.11M
Float 7.00M
Short Interest 379.75K
Financial Strength
Revenue (TTM) $353,838,000
Earnings (TTM) -$266,326,000
Quick Ratio 2.1:1
Current Ratio 3.1:1
Total Debt/Equity 0:1
Profitability
Gross Margin 96.6%
EBITDA Margin -1.7%
Profit Margin -70.8%
Powered By: FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes.
All other data is delayed at least 20 minutes.
By accessing this page, you agree to the following terms and conditions.
Real Time Stock News provided by MarketMinute.com
Stock Analysis provided by SocialPicks Conference calls info supplied by OpenCompany
Fundamental data supplied by Mergent, Inc.
Stock quote data supplied by Telekurs